SCHEMBL19852526

SCHEMBL19852526

COC(CN1C(=O)CCc2ccccc21)OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.55
DRD3 P35462 8/20 0.49
CHRM2 P08172 7/20 0.49
CHRM1 P11229 7/20 0.49
DRD2 P14416 7/20 0.49
DRD4 P21917 7/20 0.49
CHRM4 P08173 6/20 0.49
CHRM5 P08912 6/20 0.49
CHRM3 P20309 6/20 0.49
PER2 O15055 1/20 0.47
CRY2 Q49AN0 1/20 0.47
GRIN1 Q05586 1/20 0.46
GRIN2B Q13224 1/20 0.46
SLC6A2 P23975 2/20 0.46
ADRA1A P35348 2/20 0.46
SLC22A1 O15245 1/20 0.46
HTR1A P08908 1/20 0.46
ADRA2A P08913 1/20 0.46
DRD1 P21728 1/20 0.46
TBXA2R P21731 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19852470 0.86 PRMT5 (0.50) DRD3DRD2DRD4PER2CRY2
SCHEMBL7421817 0.80 POLB (0.59) POLBDRD3CHRM2CHRM1DRD2
SCHEMBL41624 0.78 MEN1 (0.40) POLBCHRM2CHRM1CHRM4CHRM5
SCHEMBL4096279 0.78 POLB (0.57) POLBDRD3CHRM2CHRM1DRD2
SCHEMBL7251698 0.78 POLB (0.57) POLBDRD3CHRM2CHRM1DRD2
SCHEMBL4097259 0.78 DRD3 (0.55) POLBDRD3CHRM2CHRM1DRD2
SCHEMBL4095573 0.78 DRD3 (0.55) POLBDRD3CHRM2CHRM1DRD2
SCHEMBL4096281 0.78 POLB (0.57) POLBDRD3CHRM2CHRM1DRD2
SCHEMBL4097262 0.78 DRD3 (0.55) POLBDRD3CHRM2CHRM1DRD2
SCHEMBL4095572 0.78 DRD3 (0.55) POLBDRD3CHRM2CHRM1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C POLB 3235/4885DRD3 290/4885CHRM2 325/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C POLB 3235/4885DRD3 290/4885CHRM2 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.